摘要
目的探讨奥沙利铂联合希罗达方案(XELOX)治疗晚期胃癌的疗效和毒副作用。方法对我院2003年5月至2005年4月间采用XELOX化疗方案治疗的晚期胃癌进行回顾性分析,并与奥沙利铂、5氟脲嘧啶和醛氢叶酸联合化疗方案(OLF)进行比较。XELOX组41例,OLF组44例。结果XELOX方案组总有效率36.5%,疾病进展时间5.5个月,OLF方案组为34.0%和5.1个月,两组间无显著性差异;主要的毒副作用腹泻、恶心、呕吐、骨髓抑制和肝功能损害两组间无显著性差异,XELOX方案组的手足综合征发生率明显高于OLF方案组(P<0.01),但都为Ⅰ-Ⅱ度反应。结论XELOX和OLF方案治疗晚期胃癌的疗效相近,毒副作用可耐受,但XELOX方案用药更方便,且在复治患者中有一定的优势。
Objective To investigate the efficacy and toxicity of oxaliplatin combined with Xeloda （XELOX） in the treatment of advanced gastric cancer. Methods Data of patients with advanced gastric cancer treated with XOLOX （ n = 41 ） from May 2003 to April 2005 were retrospectively analysed and compared with oxaliplatin, 5 - fu and leucovorin combination chemotherapy （ OLF, n = 44 ）. Results The overall response rate was 36.1% and time to disease progression （TTP） was 5.5 months in XELOX group; the corresponding values were 35% and 5.1 months respectively in OLF group, with no significant differences between the two groups. The main toxieities were diarrhea, nausea, vomit, myelosuppression and liver function injury in both group, the differences between the two groups were not significant. The incidence of hand - foot syndrome in XELOX group was significantly higher than that in OLF group, but usually was slight （ grade Ⅰ - Ⅱ ）. Conclusion The effectiveness of XELOX regimen is the same as that of OLF regimen for advanced gastric cancer and the toxicities are tolerable. But XELOX regimen is more convenient and superior to OLF regimen for recurrent patients.
出处
《临床和实验医学杂志》
2007年第7期45-46,共2页
Journal of Clinical and Experimental Medicine
关键词
晚期胃癌
希罗达
奥沙利铂
Advanced gastric cancer
Xeloda
Oxaliplatin
